A recent case report highlights the use of immune checkpoint inhibitors in treating relapsed/refractory anaplastic large cell lymphoma (ALCL). This review of the literature provides insights into potential therapeutic strategies for this challenging condition.
immune checkpoint inhibitors in relapsed refractory anaplastic large cell lymphoma alcl a case report and review of the literature
Original title: “Immune Checkpoint Inhibitors in Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL): A Case Report and Review of the Literature.”